Budoucí P/E společnosti Horizon Discovery plc
Jaká je hodnota metriky Budoucí P/E společnosti Horizon Discovery plc?
Hodnota metriky Budoucí P/E společnosti Horizon Discovery Group plc je 200.00
Jaká je definice metriky Budoucí P/E?
Budoucí poměr P/E (Forward price to earnings ratio) vyjadřuje poměr současné ceny a odhadovaného zisku na akcii v následujících dvanácti měsících.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Budoucí P/E společností v sektoru Health Care sektor na LSE ve srovnání se společností Horizon Discovery plc
Čemu se věnuje společnost Horizon Discovery plc?
Horizon Discovery Group plc, a cell engineering company, engages in the design, manufacture, and application of gene editing and gene modulation tools in the United Kingdom, the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Screening, Research Reagents, Diagnostics, and BioProduction segments. It provides custom-made and off-the-shelf (OTS) RNAi gene modulation reagents, CRISPR reagents, synthetic SGRNAs, OTS cell models, and custom cell engineering services. The company also offers pooled CRISPR screens; arrayed RNAi and CRISPR screens, drug screens, and immunology assays; and RNAi and CRISPR screening libraries; and human T-Cell CRISPR screening service to meet the requirements of immunology based research in drug discovery. In addition, it provides OTS gene-edited CHO cells and custom CHO cell lines, and custom CHO gene engineering services; and OTS cell-based reference standards, made to order reference standards, and custom cell-based reference standards to evaluate molecular assays on a research use basis. The company serves customers in academic research labs, biopharmaceutical and diagnostics companies, and contract research and manufacturing organizations. It sells its products through direct field sales channel and e-commerce platform. The company has a partnership with the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology; strategic collaboration with Mammoth Biosciences to develop CRISPR tools to provide engineered cell lines for the biopharmaceutical industry; and collaboration with St George's University Hospital, London, and the European Molecular Genetics Quality Network to develop reference material for non-invasive prenatal testing. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.
Firmy s metrikou budoucí p/e podobnou společnosti Horizon Discovery plc
- Hodnota metriky Budoucí P/E společnosti Mcewen Mining je 196.08
- Hodnota metriky Budoucí P/E společnosti 10x Genomics je 196.08
- Hodnota metriky Budoucí P/E společnosti Belo Sun Mining je 196.08
- Hodnota metriky Budoucí P/E společnosti McEwen Mining je 196.08
- Hodnota metriky Budoucí P/E společnosti CAP-XX je 196.08
- Hodnota metriky Budoucí P/E společnosti Brooks Automation je 197.84
- Hodnota metriky Budoucí P/E společnosti Horizon Discovery plc je 200.00
- Hodnota metriky Budoucí P/E společnosti Medicenna Therapeutics je 204.08
- Hodnota metriky Budoucí P/E společnosti McEwen Mining je 204.08
- Hodnota metriky Budoucí P/E společnosti IAMGOLD je 204.08
- Hodnota metriky Budoucí P/E společnosti Medicenna Therapeutics je 208.33
- Hodnota metriky Budoucí P/E společnosti TECSYS je 208.33
- Hodnota metriky Budoucí P/E společnosti Eqtec Eo ,001 je 208.33